These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 16022668)

  • 1. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.
    Yamagishi S; Imaizumi T
    Curr Pharm Des; 2005; 11(18):2279-99. PubMed ID: 16022668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end products (AGEs) and diabetic vascular complications.
    Yamagishi S; Nakamura K; Imaizumi T
    Curr Diabetes Rev; 2005 Feb; 1(1):93-106. PubMed ID: 18220586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
    Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.
    Chilelli NC; Burlina S; Lapolla A
    Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):913-9. PubMed ID: 23786818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
    Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
    Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.
    Yamagishi S; Matsui T; Nakamura K; Ueda S; Noda Y; Imaizumi T
    Curr Drug Targets; 2008 Nov; 9(11):1025-9. PubMed ID: 18991613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of diabetic angiopathies].
    Fövényi J
    Orv Hetil; 2004 Mar; 145(12):634-7. PubMed ID: 15119119
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetic microvascular complications and growth factors.
    Pfeiffer A; Schatz H
    Exp Clin Endocrinol Diabetes; 1995; 103(1):7-14. PubMed ID: 7621107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAGE (toxic AGEs) theory in diabetic complications.
    Sato T; Iwaki M; Shimogaito N; Wu X; Yamagishi S; Takeuchi M
    Curr Mol Med; 2006 May; 6(3):351-8. PubMed ID: 16712480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
    Sheetz MJ; King GL
    JAMA; 2002 Nov; 288(20):2579-88. PubMed ID: 12444865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of protein kinase C activation and the vascular complications of diabetes.
    Das Evcimen N; King GL
    Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review.
    Paul S; Ali A; Katare R
    J Diabetes Complications; 2020 Aug; 34(8):107613. PubMed ID: 32505477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic control and microvascular complications: the near-normoglycaemic experience.
    Hanssen KF; Dahl-Jørgensen K; Lauritzen T; Feldt-Rasmussen B; Brinchmann-Hansen O; Deckert T
    Diabetologia; 1986 Oct; 29(10):677-84. PubMed ID: 3542669
    [No Abstract]   [Full Text] [Related]  

  • 14. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of endothelin-1 for microvascular dysfunction in diabetes.
    Kalani M
    Vasc Health Risk Manag; 2008; 4(5):1061-8. PubMed ID: 19183753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cellular and molecular mechanisms of diabetic complications.
    King GL; Brownlee M
    Endocrinol Metab Clin North Am; 1996 Jun; 25(2):255-70. PubMed ID: 8799700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
    Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
    Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies for the chronic complications of older diabetic patients.
    Clements RS
    Am J Med; 1986 May; 80(5A):54-60. PubMed ID: 3085495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention.
    Yamagishi S; Fukami K; Ueda S; Okuda S
    Curr Drug Targets; 2007 Aug; 8(8):952-9. PubMed ID: 17691932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
    Takeuchi M; Takino J; Yamagishi S
    Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.